SLC29A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dipyridamole (SCHEMBL16119)	1.00	19/20
Dipyridamole (SCHEMBL141802)	0.83	19/20
Mopidamol (SCHEMBL9440)	0.72	19/20
SCHEMBL34996	0.73	17/20
SCHEMBL141542	0.61	16/20
SCHEMBL141541	0.54	14/20
Dilazep (SCHEMBL48830)	1.00	10/20
SCHEMBL30356	0.48	10/20
SCHEMBL29703	0.48	9/20
SCHEMBL67126	0.73	7/20
SCHEMBL77456	0.73	7/20
SCHEMBL91050	0.73	7/20
SCHEMBL98711	0.53	6/20
SCHEMBL91169	0.85	5/20
SCHEMBL63259	0.84	5/20
SCHEMBL75915	0.84	5/20
SCHEMBL91088	0.84	5/20
SCHEMBL77457	0.78	5/20
SCHEMBL76338	0.70	5/20
Nelarabine (SCHEMBL18820)	0.67	5/20

Clinical trials — most relevant to SLC29A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia	PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir	PHASE2	COMPLETED
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine	PHASE1	COMPLETED
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer	nan	UNKNOWN
Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Placental Transfer of Tenofovir	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis	nan	RECRUITING
Characterization of Breg Cells	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC29A1 binder may also engage these)

Protein	Name	Similarity
Q9JIM1	—	0.997	Q9JIM1 →
O54698	—	0.991	O54698 →
A1A4N1	—	0.990	A1A4N1 →
Q9BZD2	—	0.989	Q9BZD2 →
Q99P65	—	0.985	Q99P65 →
Q80WK7	—	0.985	Q80WK7 →
Q6GMG6	—	0.983	Q6GMG6 →
SLC29A2	Equilibrative nucleoside transporter 2	0.981	landscape →
O54699	—	0.981	O54699 →
B0S5Y3	—	0.980	B0S5Y3 →
Q61672	—	0.977	Q61672 →
B5X4H8	—	0.976	B5X4H8 →
SLC33A1	Acetyl-coenzyme A transporter 1	0.973	landscape →
Q6AYY8	—	0.971	Q6AYY8 →
A2VE54	—	0.971	A2VE54 →
SLC15A2	Solute carrier family 15 member 2	0.971	landscape →
Q99J27	—	0.971	Q99J27 →
Q4LE88	—	0.971	Q4LE88 →
P46029	—	0.970	P46029 →
Q63424	—	0.970	Q63424 →
Q9Y115	—	0.970	Q9Y115 →
Q6PB15	—	0.970	Q6PB15 →
Q944P0	—	0.969	Q944P0 →
A0A0R4ILB2	—	0.969	A0A0R4ILB2 →
Q9UPI3	—	0.969	Q9UPI3 →
Q9ES07	—	0.968	Q9ES07 →
Q53P98	—	0.968	Q53P98 →
SLC6A19	Sodium-dependent neutral amino acid transporter B(0)AT1	0.968	landscape →
Q94AA1	—	0.968	Q94AA1 →
Q84XI3	—	0.968	Q84XI3 →